Kura Oncology, Inc.

NasdaqGS:KURA Stock Report

Market Cap: US$1.0b

Kura Oncology Valuation

Is KURA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KURA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate KURA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate KURA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KURA?

Key metric: As KURA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for KURA. This is calculated by dividing KURA's market cap by their current revenue.
What is KURA's PS Ratio?
PS Ratio10x
SalesUS$104.03m
Market CapUS$1.04b

Price to Sales Ratio vs Peers

How does KURA's PS Ratio compare to its peers?

The above table shows the PS ratio for KURA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.1x
GLUE Monte Rosa Therapeutics
5.7x-27.42%US$1.0b
GERN Geron
4.1x33.76%US$759.6m
IOVA Iovance Biotherapeutics
3.9x31.42%US$968.6m
SPRY ARS Pharmaceuticals
6.6x39.22%US$946.0m
KURA Kura Oncology
10x41.84%US$1.0b

Price-To-Sales vs Peers: KURA is expensive based on its Price-To-Sales Ratio (10x) compared to the peer average (5.1x).

Price to Sales Ratio vs Industry

How does KURA's PS Ratio compare vs other companies in the US Biotechs Industry?

134 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.7x-1.79%US$26.69b
INCY Incyte
4.3x2.08%US$20.74b
BMRN BioMarin Pharmaceutical
3.4x6.33%US$10.67b
MRNA Moderna
4.4x20.13%US$9.77b
KURA 10.0xIndustry Avg. 13.1xNo. of Companies134PS020406080100+
134 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: KURA is good value based on its Price-To-Sales Ratio (10x) compared to the US Biotechs industry average (13.1x).

Price to Sales Ratio vs Fair Ratio

What is KURA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KURA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10x
Fair PS Ratio2x

Price-To-Sales vs Fair Ratio: KURA is expensive based on its Price-To-Sales Ratio (10x) compared to the estimated Fair Price-To-Sales Ratio (2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst KURA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$11.99
US$33.00
+175.23%
45.22%US$76.00US$16.00n/a11
Nov ’26US$10.27
US$27.00
+162.90%
33.28%US$40.00US$11.00n/a11
Oct ’26US$9.20
US$27.00
+193.48%
33.28%US$40.00US$11.00n/a11
Sep ’26US$7.90
US$27.00
+241.77%
33.28%US$40.00US$11.00n/a11
Aug ’26US$6.02
US$25.92
+330.51%
39.08%US$40.00US$8.00n/a12
Jul ’26US$5.60
US$25.92
+362.80%
39.08%US$40.00US$8.00n/a12
Jun ’26US$5.69
US$25.92
+355.48%
39.08%US$40.00US$8.00n/a12
May ’26US$6.49
US$28.00
+331.43%
31.71%US$40.00US$10.00n/a12
Apr ’26US$6.38
US$26.69
+318.37%
36.19%US$40.00US$10.00n/a13
Mar ’26US$7.71
US$27.69
+259.17%
32.28%US$40.00US$10.00n/a13
Feb ’26US$7.91
US$28.36
+258.50%
28.70%US$40.00US$10.00n/a14
Jan ’26US$8.71
US$28.57
+228.03%
23.02%US$37.00US$11.00n/a14
Dec ’25US$11.04
US$28.57
+158.80%
23.02%US$37.00US$11.00n/a14
Nov ’25US$16.88
US$29.64
+75.61%
16.61%US$37.00US$19.00US$10.2714
Oct ’25US$19.21
US$30.42
+58.34%
14.23%US$37.00US$22.00US$9.2012
Sep ’25US$21.06
US$30.42
+44.43%
14.23%US$37.00US$22.00US$7.9012
Aug ’25US$20.19
US$30.42
+50.65%
14.85%US$37.00US$21.00US$6.0212
Jul ’25US$21.20
US$30.42
+43.47%
14.85%US$37.00US$21.00US$5.6012
Jun ’25US$20.61
US$30.25
+46.77%
14.48%US$37.00US$21.00US$5.6912
May ’25US$20.28
US$30.25
+49.16%
14.48%US$37.00US$21.00US$6.4912
Apr ’25US$21.82
US$30.25
+38.63%
14.48%US$37.00US$21.00US$6.3812
Mar ’25US$21.59
US$30.25
+40.11%
14.48%US$37.00US$21.00US$7.7112
Feb ’25US$21.02
US$30.17
+43.51%
14.69%US$37.00US$21.00US$7.9112
Jan ’25US$14.38
US$27.88
+93.85%
23.30%US$37.00US$10.50US$8.7112
Dec ’24US$9.96
US$28.21
+183.22%
23.01%US$37.00US$10.50US$11.0412
Nov ’24US$7.99
US$29.88
+273.90%
28.73%US$47.00US$10.50US$16.8812
US$33
Fair Value
63.7% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/28 11:03
End of Day Share Price 2025/11/26 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kura Oncology, Inc. is covered by 21 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Peter LawsonBarclays
Jason ZemanskyBofA Global Research